{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T10:43:48Z","timestamp":1782902628244,"version":"3.54.5"},"reference-count":55,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2026,5,7]],"date-time":"2026-05-07T00:00:00Z","timestamp":1778112000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"vor","delay-in-days":55,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100004156","name":"Mahidol University","doi-asserted-by":"publisher","award":["FF-052\/2567"],"award-info":[{"award-number":["FF-052\/2567"]}],"id":[{"id":"10.13039\/501100004156","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004156","name":"Mahidol University","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100004156","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Immunol Immunother"],"DOI":"10.1007\/s00262-026-04406-y","type":"journal-article","created":{"date-parts":[[2026,5,7]],"date-time":"2026-05-07T19:18:21Z","timestamp":1778181501000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["\u03b1Trop2\/\u03b1CD3 bispecific protein engager-armed T cells (BATs) exhibit potent antitumor activity against nasopharyngeal carcinoma"],"prefix":"10.1007","volume":"75","author":[{"given":"Kwanpirom","family":"Suwanchiwasiri","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chalermchai","family":"Somboonpatarakun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nan","family":"Chaiyariti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Utid","family":"Suriya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Surang","family":"Chankhamhaengdecha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pa\u2011thai","family":"Yenchitsomanus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tavan","family":"Janvilisri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mutita","family":"Junking","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,7]]},"reference":[{"issue":"10192","key":"4406_CR1","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/s0140-673(19)30956-0","volume":"394","author":"YP Chen","year":"2019","unstructured":"Chen YP, Chan ATC, Le QT, Blanchard P, Sun Y, Ma J (2019) Nasopharyngeal carcinoma. Lancet 394(10192):64\u201380. https:\/\/doi.org\/10.1016\/s0140-673(19)30956-0","journal-title":"Lancet"},{"issue":"11","key":"4406_CR2","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1038\/s41571-021-00524-x","volume":"18","author":"KCW Wong","year":"2021","unstructured":"Wong KCW, Hui EP, Lo KW, Lam WKJ, Johnson D, Li L et al (2021) Nasopharyngeal carcinoma: an evolving paradigm. Nat Rev Clin Oncol 18(11):679\u2013695. https:\/\/doi.org\/10.1038\/s41571-021-00524-x","journal-title":"Nat Rev Clin Oncol"},{"issue":"4","key":"4406_CR3","doi-asserted-by":"publisher","first-page":"1070","DOI":"10.1016\/j.ijrobp.2008.09.008","volume":"74","author":"WW Xiao","year":"2009","unstructured":"Xiao WW, Han F, Lu TX, Chen CY, Huang Y, Zhao C (2009) Treatment outcomes after radiotherapy alone for patients with early-stage nasopharyngeal carcinoma. Int J Radiat Oncol Biol Phys 74(4):1070\u20131076. https:\/\/doi.org\/10.1016\/j.ijrobp.2008.09.008","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"1","key":"4406_CR4","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1016\/j.ijrobp.2010.09.011","volume":"82","author":"SF Su","year":"2012","unstructured":"Su SF, Han F, Zhao C, Chen CY, Xiao WW, Li JX et al (2012) Long-term outcomes of early-stage nasopharyngeal carcinoma patients treated with intensity-modulated radiotherapy alone. Int J Radiat Oncol Biol Phys 82(1):327\u2013333. https:\/\/doi.org\/10.1016\/j.ijrobp.2010.09.011","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"22","key":"4406_CR5","doi-asserted-by":"publisher","first-page":"2420","DOI":"10.1200\/JCO.22.00327","volume":"40","author":"Y Zhang","year":"2022","unstructured":"Zhang Y, Chen L, Hu G-Q, Zhang N, Zhu X-D, Yang K-Y et al (2022) Final overall survival analysis of gemcitabine and cisplatin induction chemotherapy in nasopharyngeal carcinoma: a multicenter, randomized phase III trial. J Clin Oncol 40(22):2420\u20132425. https:\/\/doi.org\/10.1200\/JCO.22.00327","journal-title":"J Clin Oncol"},{"issue":"8","key":"4406_CR6","doi-asserted-by":"publisher","first-page":"1252","DOI":"10.1093\/annonc\/mdf200","volume":"13","author":"RKC Ngan","year":"2002","unstructured":"Ngan RKC, Yiu HHY, Lau WH, Yau S, Cheung FY, Chan TM et al (2002) Combination gemcitabine and cisplatin chemotherapy for metastatic or recurrent nasopharyngeal carcinoma: report of a phase II study. Ann Oncol 13(8):1252\u20131258. https:\/\/doi.org\/10.1093\/annonc\/mdf200","journal-title":"Ann Oncol"},{"issue":"10054","key":"4406_CR7","doi-asserted-by":"publisher","first-page":"1883","DOI":"10.1016\/S0140-6736(16)31388-5","volume":"388","author":"L Zhang","year":"2016","unstructured":"Zhang L, Huang Y, Hong S, Yang Y, Yu G, Jia J et al (2016) Gemcitabine plus cisplatin versus fluorouracil plus cisplatin in recurrent or metastatic nasopharyngeal carcinoma: a multicentre, randomised, open-label, phase 3 trial. The Lancet 388(10054):1883\u20131892. https:\/\/doi.org\/10.1016\/S0140-6736(16)31388-5","journal-title":"The Lancet"},{"issue":"14","key":"4406_CR8","doi-asserted-by":"publisher","first-page":"1412","DOI":"10.1200\/jco.2017.77.0388","volume":"36","author":"BBY Ma","year":"2018","unstructured":"Ma BBY, Lim WT, Goh BC, Hui EP, Lo KW, Pettinger A et al (2018) Antitumor Activity of Nivolumab in Recurrent and Metastatic Nasopharyngeal Carcinoma: An International, Multicenter Study of the Mayo Clinic Phase 2 Consortium (NCI-9742). J Clin Oncol 36(14):1412\u20131418. https:\/\/doi.org\/10.1200\/jco.2017.77.0388","journal-title":"J Clin Oncol"},{"issue":"5","key":"4406_CR9","doi-asserted-by":"publisher","first-page":"2967","DOI":"10.21873\/invivo.12127","volume":"34","author":"H Sato","year":"2020","unstructured":"Sato H, Fushimi C, Okada T, Matsuki T, Kondo T, Omura GO et al (2020) Investigation of the efficacy and safety of Nivolumab in recurrent and metastatic nasopharyngeal carcinoma. In Vivo 34(5):2967\u20132972. https:\/\/doi.org\/10.21873\/invivo.12127","journal-title":"In Vivo"},{"issue":"9","key":"4406_CR10","doi-asserted-by":"publisher","first-page":"1536","DOI":"10.1038\/s41591-021-01444-0","volume":"27","author":"H-Q Mai","year":"2021","unstructured":"Mai H-Q, Chen Q-Y, Chen D, Hu C, Yang K, Wen J et al (2021) Toripalimab or placebo plus chemotherapy as first-line treatment in advanced nasopharyngeal carcinoma: a multicenter randomized phase 3 trial. Nat Med 27(9):1536\u20131543. https:\/\/doi.org\/10.1038\/s41591-021-01444-0","journal-title":"Nat Med"},{"issue":"20","key":"4406_CR11","doi-asserted-by":"publisher","first-page":"1961","DOI":"10.1001\/jama.2023.20181","volume":"330","author":"H-Q Mai","year":"2023","unstructured":"Mai H-Q, Chen Q-Y, Chen D, Hu C, Yang K, Wen J et al (2023) Toripalimab plus chemotherapy for recurrent or metastatic nasopharyngeal carcinoma: the JUPITER-02 randomized clinical trial. JAMA 330(20):1961\u20131970. https:\/\/doi.org\/10.1001\/jama.2023.20181","journal-title":"JAMA"},{"issue":"1","key":"4406_CR12","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1038\/mt.2013.242","volume":"22","author":"W-K Chia","year":"2014","unstructured":"Chia W-K, Teo M, Wang W-W, Lee B, Ang S-F, Tai W-M et al (2014) Adoptive T-cell transfer and chemotherapy in the first-line treatment of metastatic and\/or locally recurrent nasopharyngeal carcinoma. Mol Ther 22(1):132\u2013139. https:\/\/doi.org\/10.1038\/mt.2013.242","journal-title":"Mol Ther"},{"issue":"14","key":"4406_CR13","doi-asserted-by":"publisher","first-page":"2642","DOI":"10.1002\/cncr.30541","volume":"123","author":"J Huang","year":"2017","unstructured":"Huang J, Fogg M, Wirth LJ, Daley H, Ritz J, Posner MR et al (2017) Epstein-Barr virus-specific adoptive immunotherapy for recurrent, metastatic nasopharyngeal carcinoma. Cancer 123(14):2642\u20132650. https:\/\/doi.org\/10.1002\/cncr.30541","journal-title":"Cancer"},{"key":"4406_CR14","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2024.116718","volume":"175","author":"K Suwanchiwasiri","year":"2024","unstructured":"Suwanchiwasiri K, Phanthaphol N, Somboonpatarakun C, Yuti P, Sujjittjoon J, Luangwattananun P et al (2024) Bispecific T cell engager-armed T cells targeting integrin \u03b1\u03bd\u03b26 exhibit enhanced T cell redirection and antitumor activity in cholangiocarcinoma. Biomed Pharmacother 175:116718. https:\/\/doi.org\/10.1016\/j.biopha.2024.116718","journal-title":"Biomed Pharmacother"},{"issue":"Pt B","key":"4406_CR15","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2023.111012","volume":"124","author":"P Luangwattananun","year":"2023","unstructured":"Luangwattananun P, Sangsuwannukul T, Supimon K, Thuwajit C, Chieochansin T, Sa-Nguanraksa D et al (2023) Anti-PD-L1 \u00d7 anti-CD3 bispecific T-cell engager-armed T cells can overcome immunosuppression and redirect T cells to kill breast cancer cells expressing PD-L1. Int Immunopharmacol 124(Pt B):111012. https:\/\/doi.org\/10.1016\/j.intimp.2023.111012","journal-title":"Int Immunopharmacol"},{"issue":"Pt 2","key":"4406_CR16","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2024.113480","volume":"143","author":"K Supimon","year":"2024","unstructured":"Supimon K, Sangsuwannukul T, Luangwattananun P, Yenchitsomanus PT (2024) Enhanced cytotoxicity in multiple myeloma via T cells armed with bispecific T cell engager targeting B-cell maturation antigen on cancer cells and CD3 on T cells. Int Immunopharmacol 143(Pt 2):113480. https:\/\/doi.org\/10.1016\/j.intimp.2024.113480","journal-title":"Int Immunopharmacol"},{"issue":"5","key":"4406_CR17","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1016\/j.bbmt.2015.12.030","volume":"22","author":"LG Lum","year":"2016","unstructured":"Lum LG, Thakur A, Kondadasula SV, Al-Kadhimi Z, Deol A, Tomaszewski EN et al (2016) Targeting CD138-\/CD20+ clonogenic myeloma precursor cells decreases these cells and induces transferable antimyeloma immunity. Biol Blood Marrow Transplant 22(5):869\u2013878. https:\/\/doi.org\/10.1016\/j.bbmt.2015.12.030","journal-title":"Biol Blood Marrow Transplant"},{"key":"4406_CR18","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-002194","author":"LG Lum","year":"2021","unstructured":"Lum LG, Al-Kadhimi Z, Deol A, Kondadasula V, Schalk D, Tomashewski E et al (2021) Phase II clinical trial using anti-CD3 \u00d7 anti-HER2 bispecific antibody armed activated T cells (HER2 BATs) consolidation therapy for HER2 negative (0-2+) metastatic breast cancer. J Immunother Cancer. https:\/\/doi.org\/10.1136\/jitc-2020-002194","journal-title":"J Immunother Cancer"},{"issue":"1","key":"4406_CR19","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1158\/1078-0432.Ccr-22-1601","volume":"29","author":"UN Vaishampayan","year":"2023","unstructured":"Vaishampayan UN, Thakur A, Chen W, Deol A, Patel M, Dobson K et al (2023) Phase II trial of Pembrolizumab and anti-CD3 x anti-HER2 bispecific antibody-armed activated T cells in metastatic castration-resistant prostate cancer. Clin Cancer Res 29(1):122\u2013133. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-22-1601","journal-title":"Clin Cancer Res"},{"issue":"1","key":"4406_CR20","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1038\/bmt.2013.133","volume":"49","author":"LG Lum","year":"2014","unstructured":"Lum LG, Thakur A, Pray C, Kouttab N, Abedi M, Deol A et al (2014) Multiple infusions of CD20-targeted T cells and low-dose IL-2 after SCT for high-risk non-Hodgkin\u2019s lymphoma: a pilot study. Bone Marrow Transplant 49(1):73\u201379. https:\/\/doi.org\/10.1038\/bmt.2013.133","journal-title":"Bone Marrow Transplant"},{"issue":"48","key":"4406_CR21","doi-asserted-by":"publisher","first-page":"28989","DOI":"10.18632\/oncotarget.25615","volume":"9","author":"DM Goldenberg","year":"2018","unstructured":"Goldenberg DM, Stein R, Sharkey RM (2018) The emergence of trophoblast cell-surface antigen 2 (TROP-2) as a novel cancer target. Oncotarget 9(48):28989\u201329006. https:\/\/doi.org\/10.18632\/oncotarget.25615","journal-title":"Oncotarget"},{"issue":"3","key":"4406_CR22","doi-asserted-by":"publisher","first-page":"109","DOI":"10.62347\/bkis3836","volume":"15","author":"L Ye","year":"2025","unstructured":"Ye L, Chen H, Wu D (2025) TROP2-targeted molecular imaging: a promising tool for precision oncology. Am J Nucl Med Mol Imaging 15(3):109\u2013123. https:\/\/doi.org\/10.62347\/bkis3836","journal-title":"Am J Nucl Med Mol Imaging"},{"issue":"9","key":"4406_CR23","first-page":"10995","volume":"8","author":"GF Guan","year":"2015","unstructured":"Guan GF, Zhang DJ, Wen LJ, Yu DJ, Zhao Y, Zhu L et al (2015) Prognostic value of TROP2 in human nasopharyngeal carcinoma. Int J Clin Exp Pathol 8(9):10995\u201311004","journal-title":"Int J Clin Exp Pathol"},{"issue":"8016","key":"4406_CR24","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1038\/s41586-024-07487-w","volume":"630","author":"J Abramson","year":"2024","unstructured":"Abramson J, Adler J, Dunger J, Evans R, Green T, Pritzel A et al (2024) Accurate structure prediction of biomolecular interactions with AlphaFold 3. Nature 630(8016):493\u2013500. https:\/\/doi.org\/10.1038\/s41586-024-07487-w","journal-title":"Nature"},{"issue":"9","key":"4406_CR25","doi-asserted-by":"publisher","first-page":"1157","DOI":"10.1002\/jcc.20035","volume":"25","author":"J Wang","year":"2004","unstructured":"Wang J, Wolf RM, Caldwell JW, Kollman PA, Case DA (2004) Development and testing of a general amber force field. J Comput Chem 25(9):1157\u20131174. https:\/\/doi.org\/10.1002\/jcc.20035","journal-title":"J Comput Chem"},{"issue":"1","key":"4406_CR26","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1002\/pro.3280","volume":"27","author":"E Jurrus","year":"2018","unstructured":"Jurrus E, Engel D, Star K, Monson K, Brandi J, Felberg LE et al (2018) Improvements to the APBS biomolecular solvation software suite. Protein Sci 27(1):112\u2013128. https:\/\/doi.org\/10.1002\/pro.3280","journal-title":"Protein Sci"},{"issue":"2","key":"4406_CR27","doi-asserted-by":"publisher","first-page":"926","DOI":"10.1063\/1.445869","volume":"79","author":"WL Jorgensen","year":"1983","unstructured":"Jorgensen WL, Chandrasekhar J, Madura JD, Impey RW, Klein ML (1983) Comparison of simple potential functions for simulating liquid water. J Chem Phys 79(2):926\u2013935. https:\/\/doi.org\/10.1063\/1.445869","journal-title":"J Chem Phys"},{"issue":"14","key":"4406_CR28","doi-asserted-by":"publisher","first-page":"6363","DOI":"10.1063\/1.1667473","volume":"120","author":"BP Uberuaga","year":"2004","unstructured":"Uberuaga BP, Anghel M, Voter AF (2004) Synchronization of trajectories in canonical molecular-dynamics simulations: observation, explanation, and exploitation. J Chem Phys 120(14):6363\u20136374. https:\/\/doi.org\/10.1063\/1.1667473","journal-title":"J Chem Phys"},{"issue":"12","key":"4406_CR29","doi-asserted-by":"publisher","first-page":"10089","DOI":"10.1063\/1.464397","volume":"98","author":"T Darden","year":"1993","unstructured":"Darden T, York D, Pedersen L (1993) Particle mesh Ewald: an N\u22c5log(N) method for Ewald sums in large systems. J Chem Phys 98(12):10089\u201310092. https:\/\/doi.org\/10.1063\/1.464397","journal-title":"J Chem Phys"},{"issue":"7","key":"4406_CR30","doi-asserted-by":"publisher","first-page":"3084","DOI":"10.1021\/ct400341p","volume":"9","author":"DR Roe","year":"2013","unstructured":"Roe DR, Cheatham TE III (2013) PTRAJ and CPPTRAJ: software for processing and analysis of molecular dynamics trajectory data. J Chem Theory Comput 9(7):3084\u20133095. https:\/\/doi.org\/10.1021\/ct400341p","journal-title":"J Chem Theory Comput"},{"issue":"5","key":"4406_CR31","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1517\/17460441.2015.1032936","volume":"10","author":"S Genheden","year":"2015","unstructured":"Genheden S, Ryde U (2015) The MM\/PBSA and MM\/GBSA methods to estimate ligand-binding affinities. Expert Opin Drug Discov 10(5):449\u2013461. https:\/\/doi.org\/10.1517\/17460441.2015.1032936","journal-title":"Expert Opin Drug Discov"},{"issue":"6","key":"4406_CR32","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1016\/S1044-579X(02)00089-5","volume":"12","author":"SP Lee","year":"2002","unstructured":"Lee SP (2002) Nasopharyngeal carcinoma and the EBV-specific T cell response: prospects for immunotherapy. Semin Cancer Biol 12(6):463\u2013471. https:\/\/doi.org\/10.1016\/S1044-579X(02)00089-5","journal-title":"Semin Cancer Biol"},{"issue":"6","key":"4406_CR33","doi-asserted-by":"publisher","first-page":"751","DOI":"10.2174\/156652409788970698","volume":"9","author":"X Li","year":"2009","unstructured":"Li X, Fasano R, Wang E, Yao KT, Marincola FM (2009) HLA associations with nasopharyngeal carcinoma. Curr Mol Med 9(6):751\u2013765. https:\/\/doi.org\/10.2174\/156652409788970698","journal-title":"Curr Mol Med"},{"issue":"11","key":"4406_CR34","doi-asserted-by":"publisher","first-page":"2401","DOI":"10.1002\/ijc.22334","volume":"120","author":"T Ogino","year":"2007","unstructured":"Ogino T, Moriai S, Ishida Y, Ishii H, Katayama A, Miyokawa N et al (2007) Association of immunoescape mechanisms with Epstein-Barr virus infection in nasopharyngeal carcinoma. Int J Cancer 120(11):2401\u20132410. https:\/\/doi.org\/10.1002\/ijc.22334","journal-title":"Int J Cancer"},{"issue":"3","key":"4406_CR35","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1080\/21645515.2018.1540828","volume":"15","author":"R Burt","year":"2019","unstructured":"Burt R, Warcel D, Fielding AK (2019) Blinatumomab, a bispecific B-cell and T-cell engaging antibody, in the treatment of B-cell malignancies. Hum Vaccin Immunother 15(3):594\u2013602. https:\/\/doi.org\/10.1080\/21645515.2018.1540828","journal-title":"Hum Vaccin Immunother"},{"key":"4406_CR36","doi-asserted-by":"publisher","DOI":"10.3390\/ijms221910640","author":"M Pav\u0161i\u010d","year":"2021","unstructured":"Pav\u0161i\u010d M (2021) Trop2 forms a stable dimer with significant structural differences within the membrane-distal region as compared to EpCAM. Int J Mol Sci. https:\/\/doi.org\/10.3390\/ijms221910640","journal-title":"Int J Mol Sci"},{"issue":"10","key":"4406_CR37","doi-asserted-by":"publisher","DOI":"10.1016\/j.isci.2021.103190","volume":"24","author":"M Sun","year":"2021","unstructured":"Sun M, Zhang H, Jiang M, Chai Y, Qi J, Gao GF et al (2021) Structural insights into the cis and trans assembly of human trophoblast cell surface antigen 2. iScience 24(10):103190. https:\/\/doi.org\/10.1016\/j.isci.2021.103190","journal-title":"iScience"},{"issue":"10","key":"4406_CR38","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics16101255","volume":"16","author":"J Deng","year":"2024","unstructured":"Deng J, Geng Z, Luan L, Jiang D, Lu J, Zhang H et al (2024) Novel anti-Trop2 nanobodies disrupt receptor dimerization and inhibit tumor cell growth. Pharmaceutics 16(10):1255. https:\/\/doi.org\/10.3390\/pharmaceutics16101255","journal-title":"Pharmaceutics"},{"issue":"4","key":"4406_CR39","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0321555","volume":"20","author":"P Kuo","year":"2025","unstructured":"Kuo P, Elboudwarej E, Zavodovskaya M, Lin KW, Lee CV, Diehl L et al (2025) Trop-2 expression in non-small cell lung cancer. PLoS ONE 20(4):e0321555. https:\/\/doi.org\/10.1371\/journal.pone.0321555","journal-title":"PLoS ONE"},{"issue":"4","key":"4406_CR40","doi-asserted-by":"publisher","first-page":"910","DOI":"10.5114\/aoms.2016.63743","volume":"14","author":"M Kapa\u0142czy\u0144ska","year":"2018","unstructured":"Kapa\u0142czy\u0144ska M, Kolenda T, Przyby\u0142a W, Zaj\u0105czkowska M, Teresiak A, Filas V et al (2018) 2D and 3D cell cultures - a comparison of different types of cancer cell cultures. Arch Med Sci 14(4):910\u2013919. https:\/\/doi.org\/10.5114\/aoms.2016.63743","journal-title":"Arch Med Sci"},{"issue":"8","key":"4406_CR41","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0183390","volume":"12","author":"SL Ross","year":"2017","unstructured":"Ross SL, Sherman M, McElroy PL, Lofgren JA, Moody G, Baeuerle PA et al (2017) Bispecific T cell engager (BiTE\u00ae) antibody constructs can mediate bystander tumor cell killing. PLoS ONE 12(8):e0183390. https:\/\/doi.org\/10.1371\/journal.pone.0183390","journal-title":"PLoS ONE"},{"issue":"5","key":"4406_CR42","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1016\/s1074-7613(00)00066-2","volume":"13","author":"H Liu","year":"2000","unstructured":"Liu H, Rhodes M, Wiest DL, Vignali DA (2000) On the dynamics of TCR:CD3 complex cell surface expression and downmodulation. Immunity 13(5):665\u2013675. https:\/\/doi.org\/10.1016\/s1074-7613(00)00066-2","journal-title":"Immunity"},{"issue":"12","key":"4406_CR43","doi-asserted-by":"publisher","first-page":"1930","DOI":"10.3324\/haematol.2012.082248","volume":"98","author":"R Wong","year":"2013","unstructured":"Wong R, Pepper C, Brennan P, Nagorsen D, Man S, Fegan C (2013) Blinatumomab induces autologous T-cell killing of chronic lymphocytic leukemia cells. Haematologica 98(12):1930\u20131938. https:\/\/doi.org\/10.3324\/haematol.2012.082248","journal-title":"Haematologica"},{"issue":"10","key":"4406_CR44","doi-asserted-by":"publisher","first-page":"2305","DOI":"10.1158\/1078-0432.Ccr-14-2280","volume":"21","author":"LG Lum","year":"2015","unstructured":"Lum LG, Thakur A, Al-Kadhimi Z, Colvin GA, Cummings FJ, Legare RD et al (2015) Targeted T-cell therapy in stage IV breast cancer: a phase I clinical trial. Clin Cancer Res 21(10):2305\u20132314. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-14-2280","journal-title":"Clin Cancer Res"},{"issue":"3-4","key":"4406_CR45","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1080\/08830180902978120","volume":"28","author":"F Zhou","year":"2009","unstructured":"Zhou F (2009) Molecular mechanisms of IFN-gamma to up-regulate MHC class I antigen processing and presentation. Int Rev Immunol 28(3\u20134):239\u2013260. https:\/\/doi.org\/10.1080\/08830180902978120","journal-title":"Int Rev Immunol"},{"issue":"1","key":"4406_CR46","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-025-07418-x","volume":"23","author":"CP Gan","year":"2025","unstructured":"Gan CP, Kok SY, Lee BKB, Zulaziz N, Cheong SC, Savelyeva N et al (2025) Cancer vaccine overcomes immune evasion of nasopharyngeal carcinoma by restoring MHC-I through transcriptional regulation of NLRC5. J Transl Med 23(1):1414. https:\/\/doi.org\/10.1186\/s12967-025-07418-x","journal-title":"J Transl Med"},{"issue":"2","key":"4406_CR47","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1084\/jem.20070104","volume":"204","author":"G Trinchieri","year":"2007","unstructured":"Trinchieri G (2007) Interleukin-10 production by effector T cells: Th1 cells show self control. J Exp Med 204(2):239\u2013243. https:\/\/doi.org\/10.1084\/jem.20070104","journal-title":"J Exp Med"},{"issue":"4","key":"4406_CR48","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1111\/j.1365-2567.2006.02521.x","volume":"120","author":"N Peshes-Yaloz","year":"2007","unstructured":"Peshes-Yaloz N, Rosen D, Sondel PM, Krammer PH, Berke G (2007) Up-regulation of Fas (CD95) expression in tumour cells in vivo. Immunology 120(4):502\u2013511. https:\/\/doi.org\/10.1111\/j.1365-2567.2006.02521.x","journal-title":"Immunology"},{"issue":"21","key":"4406_CR49","doi-asserted-by":"publisher","first-page":"10193","DOI":"10.1073\/pnas.90.21.10193","volume":"90","author":"T Matsusaka","year":"1993","unstructured":"Matsusaka T, Fujikawa K, Nishio Y, Mukaida N, Matsushima K, Kishimoto T et al (1993) Transcription factors NF-IL6 and NF-kappa B synergistically activate transcription of the inflammatory cytokines, interleukin 6 and interleukin 8. Proc Natl Acad Sci U S A 90(21):10193\u201310197. https:\/\/doi.org\/10.1073\/pnas.90.21.10193","journal-title":"Proc Natl Acad Sci U S A"},{"key":"4406_CR50","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1016\/j.molimm.2018.05.004","volume":"101","author":"C Yan","year":"2018","unstructured":"Yan C, Deng C, Liu X, Chen Y, Ye J, Cai R et al (2018) TNF-\u03b1 induction of IL-6 in alveolar type II epithelial cells: contributions of JNK\/c-Jun\/AP-1 element, C\/EBP\u03b4\/C\/EBP binding site and IKK\/NF-\u03baB p65\/\u03baB site. Mol Immunol 101:585\u2013596. https:\/\/doi.org\/10.1016\/j.molimm.2018.05.004","journal-title":"Mol Immunol"},{"issue":"4","key":"4406_CR51","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1038\/nrclinonc.2018.8","volume":"15","author":"DE Johnson","year":"2018","unstructured":"Johnson DE, O\u2019Keefe RA, Grandis JR (2018) Targeting the IL-6\/JAK\/STAT3 signalling axis in cancer. Nat Rev Clin Oncol 15(4):234\u2013248. https:\/\/doi.org\/10.1038\/nrclinonc.2018.8","journal-title":"Nat Rev Clin Oncol"},{"issue":"4","key":"4406_CR52","doi-asserted-by":"publisher","first-page":"1396","DOI":"10.1182\/blood-2004-06-2364","volume":"105","author":"N Askenasy","year":"2005","unstructured":"Askenasy N, Yolcu ES, Yaniv I, Shirwan H (2005) Induction of tolerance using Fas ligand: a double-edged immunomodulator. Blood 105(4):1396\u20131404. https:\/\/doi.org\/10.1182\/blood-2004-06-2364","journal-title":"Blood"},{"key":"4406_CR53","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1192303","author":"Y Pan","year":"2023","unstructured":"Pan Y, Yang W, Tang B, Wang X, Zhang Q, Li W et al (2023) The protective and pathogenic role of Th17 cell plasticity and function in the tumor microenvironment. Front Immunol. https:\/\/doi.org\/10.3389\/fimmu.2023.1192303","journal-title":"Front Immunol"},{"issue":"1","key":"4406_CR54","doi-asserted-by":"publisher","first-page":"87","DOI":"10.3390\/ijms23010087","volume":"23","author":"R Erber","year":"2022","unstructured":"Erber R, Spoerl S, Mamilos A, Krupar R, Hartmann A, Ruebner M et al (2022) Impact of Spatially Heterogeneous Trop-2 Expression on Prognosis in Oral Squamous Cell Carcinoma. Int J Mol Sci 23(1):87. https:\/\/doi.org\/10.3390\/ijms23010087","journal-title":"Int J Mol Sci"},{"issue":"11","key":"4406_CR55","doi-asserted-by":"publisher","first-page":"1411","DOI":"10.1093\/carcin\/bgy095","volume":"39","author":"J Rem\u0161\u00edk","year":"2018","unstructured":"Rem\u0161\u00edk J, Bin\u00f3 L, Kahounov\u00e1 Z, Kharaishvili G, \u0160imeckov\u00e1 \u0160, Fedr R et al (2018) Trop-2 plasticity is controlled by epithelial-to-mesenchymal transition. Carcinogenesis 39(11):1411\u20131418. https:\/\/doi.org\/10.1093\/carcin\/bgy095","journal-title":"Carcinogenesis"}],"container-title":["Cancer Immunology, Immunotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00262-026-04406-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-026-04406-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-026-04406-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T09:46:55Z","timestamp":1782899215000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00262-026-04406-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,7]]},"references-count":55,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2026,7]]}},"alternative-id":["4406"],"URL":"https:\/\/doi.org\/10.1007\/s00262-026-04406-y","relation":{},"ISSN":["1432-0851"],"issn-type":[{"value":"1432-0851","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,7]]},"assertion":[{"value":"10 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}},{"value":"Written informed consent was obtained from all participants prior to their inclusion in the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to publication"}},{"value":"The study was conducted in compliance with the principles outlined in the Declaration of Helsinki and was approved by the Siriraj Institutional Review Board (SIRB) of the Faculty of Medicine Siriraj Hospital, Mahidol University (COA No. Si 819\/2022).","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}],"article-number":"174"}}